Linagliptin

by AdamStanislav - uploaded on April 26, 2017, 8:03 pm

Quoth Wikipedia ever more:



Linagliptin (INN, previously known as BI-1356, marketed under trade names Tradjenta (U.S.) and Trajenta (worldwide)) is a dipeptidyl peptidase-4 inhibitor developed by Boehringer Ingelheim for treatment of diabetes mellitus type 2.



Once-daily linagliptin was approved by the U.S. Food and Drug Administration (FDA) on 2 May 2011 for treatment of type 2 diabetes. It is being marketed by Boehringer Ingelheim and Lilly.



Linagliptin may cause severe joint pain.